Next-generation metabolic therapy that activates three receptors simultaneously — GLP-1, GIP, and glucagon — for appetite control, body fat reduction, and advanced metabolic balance. Each pen contains 50 mg of Retatrutide in 3 ml of sterile solution. Manufactured by ZENYX MED in Basel, Switzerland.
Each prefilled Zenyx® Retatrutide pen contains 3 ml of sterile solution, providing 5 full doses of 0.6 ml. A triple GLP-1, GIP, and glucagon receptor agonist, with a pH between 6.5 and 7.5.
Administered once weekly. Start with the lowest dose to minimize gastrointestinal effects and increase progressively under professional guidance.
⚠ Do not exceed 60 clicks in any 7-day period.
Do not use Zenyx® Retatrutide in case of allergy to retatrutide or any component of the formula, nor in cases of prior hypersensitivity to GLP-1 receptor agonists.
Like any injectable medication, it may cause side effects — mostly mild and transient, predominantly gastrointestinal. In case of severe symptoms, seek immediate medical attention.
Before first use: 2 °C – 8 °C (refrigerated).
After first use: below 25 °C.
